IDEAS home Printed from https://ideas.repec.org/f/pto443.html
   My authors  Follow this author

Adrian Towse

Personal Details

First Name:Adrian
Middle Name:
Last Name:Towse
Suffix:
RePEc Short-ID:pto443
[This author has chosen not to make the email address public]

Affiliation

Office of Health Economics

London, United Kingdom
http://www.ohe.org/
RePEc:edi:ohecouk (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Books

Working papers

  1. Mestre-Ferrandiz, J. & Berdud, M. & Towse, A., 2018. "Review of CRA's Report "Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe"," Consulting Reports 001944, Office of Health Economics.
  2. Pearson, S. & Dreitlein, B. & Towse, A. & Hampson, G. & Henshall, C., 2018. "Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions," Research Papers 001998, Office of Health Economics.
  3. Hampson, G. & Towse, A. & Dreitlein, B. & Henshall, C. & Pearson, S., 2018. "Real World Evidence for Coverage Decisions: Opportunities and Challenges," Research Papers 001997, Office of Health Economics.
  4. Towse, A. & Garau, M., 2018. "Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence," Consulting Reports 001978, Office of Health Economics.
  5. Ferraro, J. & Towse, A. & Mestre-Ferrandiz, J., 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefings 001842, Office of Health Economics.
  6. Barnsley, P. & Hampson, G. & Towse, A. & Henshall, C., 2017. "Transferability of HTA," Briefings 001837, Office of Health Economics.
  7. Towse, A. & Henshall, C., 2017. "HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?," Briefings 001838, Office of Health Economics.
  8. Neri, M. & Towse, A., 2017. "Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?," Briefings 001922, Office of Health Economics.
  9. Hampson, G. & Towse, A. & Henshall, C., 2017. "How can HTA meet the needs of health system and government decision makers?," Briefings 001836, Office of Health Economics.
  10. Hernandez-Villafuerte, K. & Garau, M. & Towse, A. & Garrison, L. & Grewal, S., 2017. "Policy Options for Formulary Development in Middle-income Countries," Consulting Reports 001784, Office of Health Economics.
  11. Hampson, G. & Lichten, C. & Berdud, M. & Pollitt, A. & Mestre-Ferrandiz, J. & Sussex, J. & Towse, A., 2017. "'Macro' Evaluation of the NIHR Oxford Biomedical Research Centre," Research Papers 001848, Office of Health Economics.
  12. Karlsberg Schaffer, S. & West, P. & Towse, A. & Henshall, C. & Mestre-Ferrandiz, J. & Masterson, R. & Fischer, A., 2017. "Additional Elements of Value for Health Technology Assessment Decisions," Briefings 001851, Office of Health Economics.
  13. Marsden, G. & Towse, A. & Pearson, S.D & Dreitlein, B. & Henshall, C., 2017. "Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value," Research Papers 001811, Office of Health Economics.
  14. Hampson, G. & Towse, A. & Henshall, C., 2017. "Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies," Briefings 001835, Office of Health Economics.
  15. Marsden, G. & Towse, A., 2017. "Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?," Consulting Reports 001802, Office of Health Economics.
  16. Marsden, G. & Martin, A. & Zamora, B. & Exley, J. & Sussex, J. & Towse, A., 2016. "Four Case Studies to Explore the Added Value of Oxford AHSN," Consulting Reports 001743, Office of Health Economics.
  17. Barnsley, P. & Cubi-Molla, P. & Fischer, A. & Towse, A., 2016. "Uncertainty and Risk in HTA Decision Making," Research Papers 001764, Office of Health Economics.
  18. Karlsberg Schaffer, S. & Cubi-Molla, P. & Devlin, N. & Towse, A., 2016. "Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making," Consulting Reports 001699, Office of Health Economics.
  19. Cole, A. & Lundqvist, A. & Lorgelly, P. & Norrlid, H. & Karlsberg Schaffer, S. & Lewis, F. & Hernandez-Villafuerte, K. & Lindgren, P. & Garau, M. & Welin, K-O & Bianchi, S. & Althin, R. & O'Neill, P. , 2016. "Improving Efficiency and Resource Allocation in Future Cancer Care," Consulting Reports 001748, Office of Health Economics.
  20. Cole, A. & Chan, A. & Mujoomdar, M. & Pichler, F. & Towse, A., 2016. "How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?," Briefings 001740, Office of Health Economics.
  21. Mestre-Ferrandiz, J. & Towse, A. & Dellamano, R. & Pistollato, M., 2015. "Multi-indication Pricing: Pros, Cons and Applicability to the UK," Seminar Briefings 001653, Office of Health Economics.
  22. Cole, A. & Garrison, L. & Mestre-Ferrandiz, J. & Towse, A., 2015. "Data Governance Arrangements for Real-World Evidence," Consulting Reports 001660, Office of Health Economics.
  23. Hernandez-Villafuerte, K. & Li, R. & Towse, A. & Chalkidou, K., 2015. "International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa," Occasional Papers 001600, Office of Health Economics.
  24. Rejon-Parrilla, J.C & Hernandez-Villafuerte, K. & Shah, K. & Mestre-Ferrandiz, J. & Garrison, L. & Towse, A., 2014. "The Expanding Value Footprint of Oncology Treatments," Consulting Reports 000050, Office of Health Economics.
  25. Mestre-Ferrandiz, J. & Towse, A., 2014. "What is the Role of HTA for Biosimilars?," Briefings 000075, Office of Health Economics.
  26. Towse, A., 2014. "Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?," Occasional Papers 001561, Office of Health Economics.
  27. Barnsley, P. & Towse, A. & Karlsberg Schaffer, S. & Sussex, J., 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Papers 000106, Office of Health Economics.
  28. Garau, M. & Shah, K. & Sharma, P. & Towse, A., 2013. "Exploring the link between health and wealth in decision making," Research Papers 000037, Office of Health Economics.
  29. Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz, 2012. "Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context," NBER Working Papers 18593, National Bureau of Economic Research, Inc.
  30. Garau, M. & Towse, A. & Garrison, L. & Housman, L. & Ossa, D., 2012. "Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?," Research Papers 000160, Office of Health Economics.
  31. Towse, A. & Garrison, L. & Puig-Peiro, R., 2012. "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Papers 000167, Office of Health Economics.
  32. Garau, M. & Towse, A. & Danzon, P., 2011. "Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?," Occasional Papers 000191, Office of Health Economics.
  33. Towse, A. & Devlin, N. & Hawe, E. & Garrison, L., 2011. "The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response," Consulting Reports 000192, Office of Health Economics.
  34. Sussex, J. & Towse, A. & Devlin, N., 2011. "Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches," Research Papers 000177, Office of Health Economics.
  35. Towse, A. & Sharma, P., 2011. "Incentives for R&D for New Antimicrobial Drugs," Research Papers 000188, Office of Health Economics.
  36. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2011. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement," NBER Working Papers 17174, National Bureau of Economic Research, Inc.
  37. Mestre-Ferrandiz, J. & Puig-Peiro, R. & Towse, A., 2010. "Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe," Consulting Reports 000212, Office of Health Economics.
  38. Garau, M. & Shah, K. & Mason, A.R & Wang, Q. & Towse, A. & Drummond, M.F, 2010. "Using QALYs in Cancer: Review of the Methodological Limitations," Research Papers 000211, Office of Health Economics.
  39. Sharma, P. & Towse, A., 2010. "New Drugs to Tackle Antimicrobial Resistance: EU Policy Options," Occasional Papers 000216, Office of Health Economics.
  40. Garau, M. & Shah, K. & Towse, A. & Wang, Q. & Drummond, M.F & Mason, A. R., 2009. "Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience," Consulting Reports 000234, Office of Health Economics.
  41. Chauhan, D. & Towse, A. & Mestre-Ferrandiz, J., 2008. "The Market for Biosimilars: Evolution and Policy Options," Briefings 000238, Office of Health Economics.
  42. Gray, A. & Fenn, P. & Garau, M. & Pritchard, C. & Godber, E. & Towse, A., 2006. "Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions," Consulting Reports 000265, Office of Health Economics.
  43. Towse, A. & Buxton, M., 2006. "Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds," Briefings 000267, Office of Health Economics.
  44. Towse, A. & Fenn, P. & Gray, A. & Rickman, N. & Salinas, R., 2003. "Reducing Harm to Patients in the National Health Service. Will the Government's Compensation Proposals Help?," Briefings 000484, Office of Health Economics.
  45. Towse, A. & Drummond, M.F, 1998. "From Efficacy to Cost-Effectiveness," Briefings 000438, Office of Health Economics.
  46. Cave, M. & Towse, A., 1997. "Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry," Briefings 000427, Office of Health Economics.

Articles

  1. Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H., 2017. "Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation," Health Policy, Elsevier, vol. 121(10), pages 1025-1030.
  2. Mikel Berdud & Adrian Towse & Hannah Kettler, 2016. "Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria," Oxford Review of Economic Policy, Oxford University Press, vol. 32(1), pages 64-87.
  3. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.
  4. Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015. "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 263-275, July.
  5. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.
  6. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
  7. Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
  8. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
  9. Michael Drummond & Adrian Towse, 2012. "Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 1-5, February.
  10. Adrian Towse & Priya Sharma, 2011. "Incentives for R&D for New Antimicrobial Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 331-350.
  11. Michael Drummond & Anne Mason & Adrian Towse, 2006. "The desirability and feasibility of economic studies of drugs post-launch," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 5-6, March.
  12. Diego Ossa & Adrian Towse, 2004. "Genetic screening, health care and the insurance industry," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 116-121, May.
  13. Adrian Towse & Patricia Danzon, 1999. "Medical negligence and the NHS: an economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(2), pages 93-101, March.
  14. Mason, Anne & Drummond, Michael & Towse, Adrian, 1999. "Is disease management relevant in Europe: some evidence from the United Kingdom," Health Policy, Elsevier, vol. 48(1), pages 69-77, July.
  15. Adrian Towse, 1994. "The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8," Health Economics, John Wiley & Sons, Ltd., vol. 3(5), pages 347-348, September.

Books

  1. Mestre-Ferrandiz, J. & Sussex, J. & Towse, A., 2012. "The R&D Cost of a New Medicine," Monographs, Office of Health Economics, number 000135.
  2. Sharma, P. & Towse, A., 2011. "New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options," Monographs, Office of Health Economics, number 000184.
  3. Mattison, N. & Mestre-Ferrandiz, J. & Towse, A. eds, 2010. "Biosimilars: How Much Entry and Price Competition Will Result?," Monographs, Office of Health Economics, number 000195.
  4. Mason, A.R & Towse, A., 2008. "The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way," Monographs, Office of Health Economics, number 000242.
  5. Mason, A.R & Drummond, M.F & Towse, A., 2006. "Economic Post-Launch Studies: Matching the Desirable with the Feasible," Monographs, Office of Health Economics, number 000268.
  6. Kettler, H. & Towse, A., 2002. "Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty," Monographs, Office of Health Economics, number 000479.
  7. Mason, A.R & Towse, A. & Drummond, M.F & Cooke, J., 2002. "Influencing Prescribing in a Primary Care Led NHS," Monographs, Office of Health Economics, number 000476.
  8. Towse, A. & Pritchard, C. & Devlin, N. eds, 2002. "Cost-Effectiveness Thresholds: Economic and ethical issues," Monographs, Office of Health Economics, number 000473.
  9. Mason, A.R & Towse, A. & Drummond, M.F, 1999. "Disease Management, the NHS and the Pharmaceutical Industry," Monographs, Office of Health Economics, number 000446.
  10. Towse, A. ed, 1997. "Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?," Monographs, Office of Health Economics, number 000423.
  11. Towse, A. ed, 1995. "Financing Health Care in the UK: A Discussion of NERA's Prototype Model to Replace the NHS," Monographs, Office of Health Economics, number 000409.
  12. Towse, A. ed, 1995. "Industrial Policy and the Pharmaceutical Industry," Monographs, Office of Health Economics, number 000414.
  13. Hale, D. & Towse, A., 1995. "Value of the Pharmaceutical Industry to the UK Economy," Monographs, Office of Health Economics, number 000415.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 16 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (13) 2011-07-13 2018-05-14 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-28. Author is listed
  2. NEP-SEA: South East Asia (5) 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21. Author is listed
  3. NEP-COM: Industrial Competition (3) 2011-07-13 2012-12-15 2018-05-21
  4. NEP-ENV: Environmental Economics (2) 2018-05-21 2018-05-28
  5. NEP-ENE: Energy Economics (1) 2018-05-28
  6. NEP-EUR: Microeconomic European Issues (1) 2018-05-21
  7. NEP-HME: Heterodox Microeconomics (1) 2011-07-13
  8. NEP-IAS: Insurance Economics (1) 2018-05-21
  9. NEP-IPR: Intellectual Property Rights (1) 2018-05-21
  10. NEP-PPM: Project, Program & Portfolio Management (1) 2018-05-28

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Adrian Towse should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.